The Latest Analyst Ratings For Catalyst Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have recently evaluated Catalyst Pharmaceuticals (NASDAQ:CPRX) with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased by 9.77% to $29.2. Key analysts from firms like HC Wainwright & Co., Citigroup, Truist Securities, and Oppenheimer have raised their price targets, reflecting positive sentiment towards the company's future performance.
August 12, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catalyst Pharmaceuticals has received predominantly bullish ratings from analysts, with the average 12-month price target rising by 9.77% to $29.2. Analysts from HC Wainwright & Co., Citigroup, and Truist Securities have raised their price targets, indicating positive sentiment towards the company's future performance.
The increase in the average price target and the predominantly bullish ratings from multiple reputable analysts suggest a positive short-term impact on CPRX's stock price. The raised price targets from key firms indicate strong confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100